Segment Information (Tables)

3 Months Ended

Mar. 31, 2023

The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.


	Net Sales to External Customers				Operating Earnings
	Three Months Ended March 31				Three Months Ended March 31
(in millions)	2023		2022		2023		2022
Established Pharmaceutical Products	$	1,189	$	1,147	$	300	$	242
Nutritional Products	1,967		1,894		380		251
Diagnostic Products	2,688		5,257		651		2,564
Medical Devices	3,900		3,594		1,078		1,083
Total Reportable Segments	9,744		11,892		2,409		4,140
Other	3		3
Net sales	$	9,747	$	11,895
Corporate functions and benefit plan costs					(77)		(114)
Net interest expense					(52)		(117)
Share-based compensation (a)					(281)		(305)
Amortization of intangible assets					(491)		(512)
Other, net (b)					54		(216)
Earnings before taxes					$	1,562	$	2,876

______________________________________


Notes:			2022 Sales and Operating Earnings for the Diagnostic Products and Medical Devices reportable segments have been updated to reflect the internal transfer of the Acelis Connected Health business from Diagnostic Products to Medical Devices on January 1, 2023.
(a)			Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.
(b)			Other, net for the three months ended March 31, 2022 includes $120 million of charges related to a voluntary recall within the Nutritional Products segment.